Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Juni 2026 08:00 ET | Quelle: BioCardia, Inc.

BioCardia Announces $4.4 Million Financing

Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full...
05. Juni 2026 08:00 ET | Quelle: BioCardia, Inc.

FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF

SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
28. Mai 2026 08:00 ET | Quelle: BioCardia, Inc.

BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure

SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
21. Mai 2026 08:00 ET | Quelle: BioCardia, Inc.

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency

– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory...
19. Mai 2026 08:00 ET | Quelle: BioCardia, Inc.

BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
15. Mai 2026 08:00 ET | Quelle: BioCardia, Inc.

BioCardia Reports First Quarter 2026 Business Highlights and Financial Results

SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
11. Mai 2026 17:10 ET | Quelle: BioCardia, Inc.

BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
08. Mai 2026 08:00 ET | Quelle: BioCardia, Inc.

BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways

SUNNYVALE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
28. April 2026 08:00 ET | Quelle: BioCardia, Inc.

BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures

SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
20. April 2026 08:00 ET | Quelle: BioCardia, Inc.

BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

Nächste Seite